The pharmaceutical community is excited about the new drug, a dual-action therapy showing significant benefits in preliminary trials . This new compound, a incretin receptor agonist alongside a glucose-dependent insulinotropic molecule , appears to effectively reduce body mass and positively affect metabolic markers. Experts are suggesting that it